Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
efficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis.
background: available evidence shows that tetracycline family has cellular and molecular mechanisms to protect neurons and oligodendrocytes by modulating matrix metalloproteinases. we tried to compare the effectiveness of intramuscular and subcutaneous interferon beta-1a (inf-β1a) in combination with oral doxycycline among patient with relapsing remitting multiple sclerosis (rrms) and secondary...
متن کاملFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
متن کاملEfficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis
BACKGROUND Available evidence shows that tetracycline family has cellular and molecular mechanisms to protect neurons and oligodendrocytes by modulating matrix metalloproteinases. We tried to compare the effectiveness of intramuscular and subcutaneous interferon beta-1a (INF-β1a) in combination with oral doxycycline among patient with relapsing remitting multiple sclerosis (RRMS) and secondary ...
متن کاملMixed panniculitis secondary to interferon beta-1a therapy in a woman with multiple sclerosis.
Interferon beta was approved in Spain in 1995 for the treatment of progressive multiple sclerosis. There are 2 main types, interferon beta-1a and 1b, both of which are sold in a variety of formulations, resulting in a range of responses to the same molecule. Local skin reactions are a common adverse effect, and are usually self-limiting. By contrast, panniculitis and lipoatrophy are very rare, ...
متن کاملMixed Panniculitis Secondary to Interferon Beta-1a Therapy in a Woman With Multiple Sclerosis
Interferon beta was approved in Spain in 1995 for the treatment of progressive multiple sclerosis. There are 2 main types, interferon beta-1a and 1b, both of which are sold in a variety of formulations, resulting in a range of responses to the same molecule. Local skin reactions are a common adverse effect, and are usually self-limiting. By contrast, panniculitis and lipoatrophy are very rare, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Neurology
سال: 2008
ISSN: 0003-9942
DOI: 10.1001/archneurol.2007.41